PortalPublikationenReduced CD147 expression is linked to ERG fusion-positive pr...

Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy

Standard

Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. / Grupp, Katharina; Höhne, Thorsten Simon; Prien, Kristina; Hube-Magg, Claudia; Tsourlakis, Maria Christina; Sirma, Hüseyin; Pham, Taher; Heinzer, Hans; Graefen, Markus; Michl, Uwe; Simon, Ronald; Wilczak, Waldemar; Izbicki, Jakob; Sauter, Guido; Minner, Sarah; Schlomm, Thorsten; Steurer, Stefan.

in: EXP MOL PATHOL, Jahrgang 95, Nr. 2, 01.10.2013, S. 227-34.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Grupp, K, Höhne, TS, Prien, K, Hube-Magg, C, Tsourlakis, MC, Sirma, H, Pham, T, Heinzer, H, Graefen, M, Michl, U, Simon, R, Wilczak, W, Izbicki, J, Sauter, G, Minner, S, Schlomm, T & Steurer, S 2013, 'Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy', EXP MOL PATHOL, Jg. 95, Nr. 2, S. 227-34. https://doi.org/10.1016/j.yexmp.2013.08.002

APA

Grupp, K., Höhne, T. S., Prien, K., Hube-Magg, C., Tsourlakis, M. C., Sirma, H., Pham, T., Heinzer, H., Graefen, M., Michl, U., Simon, R., Wilczak, W., Izbicki, J., Sauter, G., Minner, S., Schlomm, T., & Steurer, S. (2013). Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. EXP MOL PATHOL, 95(2), 227-34. https://doi.org/10.1016/j.yexmp.2013.08.002

Vancouver

Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. EXP MOL PATHOL. 2013 Okt 1;95(2):227-34. https://doi.org/10.1016/j.yexmp.2013.08.002

Bibtex

@article{43c3d1e8eecf46d48c6e1f7f0d470672,
title = "Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy",
abstract = "The extracellular matrix metalloproteinase inducer CD147 has been suggested as a prognostic marker in prostate cancer. CD147 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, ERG status and deletions on PTEN, 3p13, 6q15 and 5q21. CD147 expression was strong in benign prostatic glands and often reduced in prostate cancers. CD147 immunostaining was found in 71.7% of 7628 interpretable cases. CD147 staining was considered strong in 34.6%, moderate in 24.3% and weak in 12.8% of cancers while 28.3% did not show any CD147 reactivity. Reduced CD147 staining was strongly associated with both TMPRSS2-ERG-rearrangement and ERG expression (p<0.0001 each). Within the subgroups of ERG positive and negative cancers, deletions of PTEN, 3p13, 6q15 and 5q21 were unrelated to the CD147 expression status. Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers. There was a marginal, but statistically significant, association of reduced CD147 expression with early biochemical recurrence (p=0.0296). The significant reduction of CD147 expression in ERG positive prostate cancer provides further evidence for marked biological differences between {"}fusion type{"} and {"}non-fusion type{"} prostate cancer. Despite a weak association with PSA recurrence, CD147 cannot be considered a relevant prognostic biomarker.",
keywords = "Adult, Aged, Antigens, CD147, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Middle Aged, Neoplasm Recurrence, Local, Oncogene Proteins, Fusion, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Tissue Array Analysis, Tumor Markers, Biological",
author = "Katharina Grupp and H{\"o}hne, {Thorsten Simon} and Kristina Prien and Claudia Hube-Magg and Tsourlakis, {Maria Christina} and H{\"u}seyin Sirma and Taher Pham and Hans Heinzer and Markus Graefen and Uwe Michl and Ronald Simon and Waldemar Wilczak and Jakob Izbicki and Guido Sauter and Sarah Minner and Thorsten Schlomm and Stefan Steurer",
note = "{\textcopyright} 2013.",
year = "2013",
month = oct,
day = "1",
doi = "10.1016/j.yexmp.2013.08.002",
language = "English",
volume = "95",
pages = "227--34",
journal = "EXP MOL PATHOL",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy

AU - Grupp, Katharina

AU - Höhne, Thorsten Simon

AU - Prien, Kristina

AU - Hube-Magg, Claudia

AU - Tsourlakis, Maria Christina

AU - Sirma, Hüseyin

AU - Pham, Taher

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Michl, Uwe

AU - Simon, Ronald

AU - Wilczak, Waldemar

AU - Izbicki, Jakob

AU - Sauter, Guido

AU - Minner, Sarah

AU - Schlomm, Thorsten

AU - Steurer, Stefan

N1 - © 2013.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - The extracellular matrix metalloproteinase inducer CD147 has been suggested as a prognostic marker in prostate cancer. CD147 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, ERG status and deletions on PTEN, 3p13, 6q15 and 5q21. CD147 expression was strong in benign prostatic glands and often reduced in prostate cancers. CD147 immunostaining was found in 71.7% of 7628 interpretable cases. CD147 staining was considered strong in 34.6%, moderate in 24.3% and weak in 12.8% of cancers while 28.3% did not show any CD147 reactivity. Reduced CD147 staining was strongly associated with both TMPRSS2-ERG-rearrangement and ERG expression (p<0.0001 each). Within the subgroups of ERG positive and negative cancers, deletions of PTEN, 3p13, 6q15 and 5q21 were unrelated to the CD147 expression status. Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers. There was a marginal, but statistically significant, association of reduced CD147 expression with early biochemical recurrence (p=0.0296). The significant reduction of CD147 expression in ERG positive prostate cancer provides further evidence for marked biological differences between "fusion type" and "non-fusion type" prostate cancer. Despite a weak association with PSA recurrence, CD147 cannot be considered a relevant prognostic biomarker.

AB - The extracellular matrix metalloproteinase inducer CD147 has been suggested as a prognostic marker in prostate cancer. CD147 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence, ERG status and deletions on PTEN, 3p13, 6q15 and 5q21. CD147 expression was strong in benign prostatic glands and often reduced in prostate cancers. CD147 immunostaining was found in 71.7% of 7628 interpretable cases. CD147 staining was considered strong in 34.6%, moderate in 24.3% and weak in 12.8% of cancers while 28.3% did not show any CD147 reactivity. Reduced CD147 staining was strongly associated with both TMPRSS2-ERG-rearrangement and ERG expression (p<0.0001 each). Within the subgroups of ERG positive and negative cancers, deletions of PTEN, 3p13, 6q15 and 5q21 were unrelated to the CD147 expression status. Decreased CD147 expression was significantly linked to high preoperative PSA values, high Gleason grade, advanced tumor stage (p<0.0001 each), and positive lymph node involvement (p=0.0026) in all cancers. There was a marginal, but statistically significant, association of reduced CD147 expression with early biochemical recurrence (p=0.0296). The significant reduction of CD147 expression in ERG positive prostate cancer provides further evidence for marked biological differences between "fusion type" and "non-fusion type" prostate cancer. Despite a weak association with PSA recurrence, CD147 cannot be considered a relevant prognostic biomarker.

KW - Adult

KW - Aged

KW - Antigens, CD147

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Oncogene Proteins, Fusion

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Tissue Array Analysis

KW - Tumor Markers, Biological

U2 - 10.1016/j.yexmp.2013.08.002

DO - 10.1016/j.yexmp.2013.08.002

M3 - SCORING: Journal article

C2 - 23948277

VL - 95

SP - 227

EP - 234

JO - EXP MOL PATHOL

JF - EXP MOL PATHOL

SN - 0014-4800

IS - 2

ER -